Stryker Corporation

Methodology

Stryker's orthopedic implants and medical technology generate relatively predictable earnings from procedure volumes and new product cycles. Aging demographics and robotic surgery adoption provide visibility. The calculation works well for this diversified med-tech leader with clear growth drivers from joint replacements, surgical equipment, and neurotechnology.

Methodology

Stryker consistently commands premium PEG ratios reflecting consistent execution, innovation in robotics and digital surgery, and diversified med-tech exposure. While expensive versus traditional device companies, the growth durability justifies valuations. Compare to Stryker's historical range and other diversified med-tech leaders.

Methodology

Stryker offers a meaningful dividend with decades of consecutive increases, making PEGY important for this quality medical device compounder. The dividend provides reliable income alongside consistent growth. For premium med-tech companies, dividend consistency matters as much as innovation-driven growth in attracting long-term quality investors.